Commentary
par
Berk, J., Rose, M., & Thakar, A. P.
Date de publication
2025
Géographie
USA
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Oui
Évalué par des pairs
Yes
L’objectif
This commentary is concerned with buprenorphine treatment for individuals with opioid use disorder in the fentanyl era. Despite changes in policy USA-wide that has increased the accessibility of buprenorphine, mitigating precipitated withdrawal during initiation is more of a challenge. There is a lack of clinical guidelines and best practises in area.
Constatations/points à retenir
In order to address the needs of this population, the authors highlight next research steps that need to be undertaken to advance in this field. Namely: prioritizing clinical trials, new approaches to research design, the need to categorize risk factors and exploring cotreatment of stimulant use disorder alongside opioid use treatment.
Mots clés
Barriers and enablers
Illegal drugs
Overdose
Policy/Regulatory
Stimulants
Substitution/OAT
Withdrawal
Treatment/recovery
